| 摘要 |
The treatment of an autoimmune disease, an atopic disease, transplantion rejection or GVHD or ameliorating one or more symptoms thereof involves the use of a combination therapy. The therapy involves administering to a subject an extracorporeal photopheresis and a TNF alpha antagonist. In particular, the extracorporeal photopheresis can comprise a psoralen (e.g. 8-MOP) and UVA, and the TNF alpha antagonist can be Infliximab, Adalimulab or Etanercept. |
